Roche and Alnylam partnership looking rosy already

8 September 2023
roche-700

Less than two months ago, Roche (ROG: SIX) and Alnylam Pharmaceuticals (Nasdaq: ALNY) announced a partnership to co-develop and co-commercialize zilebesiran.

Potentially worth more than $3 billion to Alnylam, the partnership is already appearing promising.

"These early results indicate the potential for zilebesiran to achieve sustained blood pressure reduction with quarterly or biannual dosing"On Friday, the companies announced that the Phase II study of the investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) had met its primary endpoint.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology